© 2026, NOVARHYTHM BIOSCIENCES.
From Late-Stage Preclinical to First-in-Human
SAR-297871 enters NovaRhythm’s portfolio as a late-stage preclinical asset supported by extensive prior data packages from Sanofi, including medicinal chemistry, pharmacology, toxicology, and human tissue studies. NovaRhythm’s development plan focuses on efficient de-risking and rapid translation to human proof-of-mechanism.
Step 1 – IND-Enabling Activities
Step 2 – IND Submission
Step 3 – Phase 1 Clinical Trial
Step 4 – Phase 2 Readiness & Strategic Options
With Phase 1 safety and PK established, NovaRhythm plans to: